From SNPedia
Defines the
CYP2C19 variant known as CYP2C19*8.
Carriers of the rs41291556(C) allele may have decreased activity and poor metabolizer (PM) phenotype. This variant is associated with a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide in vitro.[PMID 10411572]
| PharmGKB | PA162355683 |
| Name | CYP2C19:358T>C, 12711T>C, W120R, T358C |
| Annotation | This variant is the defining SNP for CYP2C19*8 and leads to decreased activity and poor metabolizer (PM) phenotype.This variant is associated with a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide in vitro. |
| Gene | CYP2C19 |
| Featue | Exon |
| Evidence | PubMed ID:10411572 |
| Drugs | mephenytoin, tolbutamide |
| Diseases | |
| Curation Level | Curated |
